Redwood Investment Management LLC Acquires Shares of 36,167 Pfizer Inc. $PFE

Key Points

• Redwood Investment Management acquired 36,167 Pfizer shares worth approximately $871,000 in the second quarter. Institutional investors and hedge funds collectively own 68.36% of Pfizer.
• Pfizer reported quarterly EPS of $0.77, exceeding the $0.68 consensus estimate, while revenue reached $15.03 billion and rose 2.6% year over year. The company also declared a quarterly dividend of $0.43 per share, representing a 6.1% annualized yield.
• Analysts maintain a generally cautious view, with Pfizer carrying a consensus “Hold” rating and an average price target of $28.28. The FDA’s approval of Pfizer and BioNTech’s updated 2026–2027 COVID-19 vaccine could provide seasonal revenue support.

Redwood Investment Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 36,167 shares of the biopharmaceutical company's stock, valued at approximately $871,000.

Several other large investors have also made changes to their positions in the business. BlackRock Inc. raised its position in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. State Street Corp lifted its holdings in Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company's stock valued at $7,481,085,000 after purchasing an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares during the period. Morgan Stanley increased its stake in shares of Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Pfizer during the fourth quarter worth about $1,830,986,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

PFE stock opened at $28.00 on Friday. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a market capitalization of $159.62 billion, a PE ratio of 36.85 and a beta of 0.34. The business has a 50 day simple moving average of $25.49 and a 200-day simple moving average of $26.29.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm's revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer's payout ratio is currently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Wall Street Analyst Weigh In

A number of equities analysts have commented on PFE shares. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Friday, July 10th. HSBC lowered Pfizer from a "buy" rating to a "hold" rating and decreased their price objective for the company from $32.00 to $28.00 in a report on Monday, July 6th. BMO Capital Markets dropped their target price on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Finally, Royal Bank Of Canada raised shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Pfizer currently has an average rating of "Hold" and an average price target of $28.28.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source